OncoLaB
OncoLaB
Antibody-Conjugated NamoGel
for Therapeutic Platform
for Therapeutic Platform
온코랩채용가이드
OncoLaBHiring Guide
Contact Us
OncoLaB
Antibody-Conjugated NamoGel
for Therapeutic Platform
for Therapeutic Platform
Development of
ANGel Platform Technology
ANGel is the next-generation immune-oncology treatment platform developed by OncoLab, standing for Antibody-conjugated NanoGel. Existing platforms for cancer treatment only meet some of the requirements for deliverability, efficacy, and sustainability, making it difficult to implement the technology and expand the pipeline. However, ANGel overcomes these shortcomings and is recognized as an innovative technology with excellent drug deliverability, efficacy, and sustainability.
ANGel
Novel Therapeutic
Platform
Platform
Hydrogel
Nanoparticle
Nanoparticle
-
Delivery
Direct s.c. injection
to tumor site -
Efficacy
Multipotent drug
formulation -
Sustainability
Long standing
with tissue region
Key Features of ANGel
-
High Delivery Capacity
ANGel has a water content of over 90%, which provides excellent flexibility and deformability, allowing for direct subcutaneous injection into solid tumor sites. In contrast to existing chemotherapy drugs, which are delivered through blood vessels and can affect not only cancer cells but also normal cells, ANGel selectively targets cancer cells, minimizing side effects. -
Outstanding Efficacy
ANGel can conjugate over 1,000 antibodies to a single nanoparticle, enabling the creation of personalized therapies loaded with various immuno-oncology agents. This maximizes the effectiveness of immuno-oncology drugs, enhancing therapeutic outcomes and blocking the immune evasion mechanisms of cancer cells. -
Exceptional Sustainability
ANGel has a strong adhesion to subcutaneous tissues, allowing it to maintain its efficacy for an extended period after subcutaneous injection, thereby inducing a sustained immune response against cancer cells.
| OncoLaB | A | L | |
|---|---|---|---|
| Product/service | ANGel | Hyaluronidase | Antibody-drug conjugate |
| Administration method |
Subcutaneous (peripheral) |
Subcutaneous | Intravenous |
| Delivery effciency |
Very high | Moderate | Moderate |
| Efficacy | Very high | Moderate | Moderate |
| Persistence | Very high | Moderate | Very high |
| Platform scalability |
Very high | Moderate | Moderate |
| Consideration | Need to confirm equivalent efficacy in clinical trials | Cannot enhance efficacy of existing drus | Need to optimize linker technology and increase yield |
Advantages and Clinical Applicability of ANGel Platform Compared to Existing Technologies
-
Outstanding Cancer Cell Targeting
Selective delivery to cancer cells minimizes side effects on normal cells. -
Personalized Treatment Capability
Various anticancer agents can be loaded according to the patient's condition. -
High Therapeutic Efficacy
Effective cancer cell destruction and increased survival rates. -
Sustained Effects
By residing in subcutaneous tissue, it allows for prolonged efficacy, prevention of recurrence, and minimization of side effects. -
Cost-Effective Development
Lower development costs and shorter development timelines compared to existing immuno-oncology drugs and antibody-drug conjugates (ADCs).